(Q34692452)

4 August 2017

1 reference

title

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target (English)

1 reference

4 August 2017

0 references

1 reference

1 reference

John F Carlquist

1

1 reference

4 August 2017

Joseph B Muhlestein

series ordinal

2

1 reference

4 August 2017

Jeffrey L Anderson

series ordinal

3

1 reference

4 August 2017

publication date

1 September 2007

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

4 August 2017

published in

1 reference

4 August 2017

volume

7

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

511-517

1 reference

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Platelet-activating factor and related lipid mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

The effect of statin therapy on lipoprotein associated phospholipase A2 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Long QT syndrome in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Biomarkers of cardiovascular disease: molecular basis and practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

Progress in unraveling the genetics of coronary artery disease and myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

The Val279Phe Variant of the Lipoprotein-Associated Phospholipase A2 Gene Is Associated with Catalytic Activities and Cardiovascular Disease in Korean Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.7.5.511

21 January 2018

Identifiers

DOI

10.1586/14737159.7.5.511

1 reference

4 August 2017

1 reference